More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

The investigational once-daily regimen DOR/ISL was effective and well-tolerated among women and men with HIV-1 infection.

Sichuan has confirmed its first-ever case of HIV-2 infection, a rare strain of the virus seldom seen in China, health ...

NICE has recommended cabotegravir, the UK’s first long-acting injectable HIV prevention drug, expanding access for people ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s ...